PO Box 1488
Warrenville, IL 60555
Phone: 331.248.7888
Email: sidp@affinity-strategies.com
Drs. Nicholas Torney (@NPT_PharmD) and Sunish Shah join Dr. Jeannette Bouchard (@jlbouchard001) to discuss our next topic in our Dosing Consult series: BID vs TID dosing for metronidazole. Deep dive into the PK/PD and real-world application of this switch with experts in this dosing strategy.
References:
- Addition of anaerobic coverage in biliary infections: Addition of anaerobic coverage for treatment of biliary tract infections: a propensity score-matched cohort study
- Eggerthella lenta and Pipercillin-tazobactam: Eggerthella lenta Bloodstream Infections Are Associated With Increased Mortality Following Empiric Piperacillin-Tazobactam (TZP) Monotherapy: A Population-based Cohort Study
- Q12H Dose Schedule in Surgery Prophylaxis: Twelve-hourly dosage schedule for oral and intravenous metronidazole
- 2018 Clinical Data on Q12H Dosing in Mixed Infections: Clinical efficacy of 12-h metronidazole dosing regimens in patients with anaerobic or mixed anaerobic infections
- 2021 Clinical Data on Q12H Dosing: Three is a crowd: Clinical outcomes of a twice daily versus a thrice daily metronidazole dosing strategy from a multicenter study
Nicholas Torney PharmD, BCPS, BCIDP
Dr. Nicholas Torney is an Infectious Diseases Clinical Pharmacy Specialist at Munson Healthcare in Traverse City, Michigan. He received his PharmD from Ferris State University and completed PGY1 and PGY2 Infectious Diseases residencies at Munson Medical Center.
Sunish Shah PharmD, BCIDP
Dr. Sunish Shah is a Clinical Pharmacy Specialist in Infectious Diseases at the University of Pittsburgh Medical Center in Pennsylvania. His research interests include management of drug-resistant bacterial infections, antimicrobial pharmacokinetics, and pharmacotherapy for the treatment of respiratory viruses.
